182912-74-9

Basic information

• Product Name: (PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21)
• Synonyms: LPFFD;BETA-SHEET BREAKER PEPTIDE IA-BETA5P;BETA-SHEET BREAKER PEPTIDE IA-BETA5;LEU-PRO-PHE-PHE-ASP;H-LEU-PRO-PHE-PHE-ASP-OH;IA-BETA5;IAB5;A-BETA42 FIBRILLOGENESIS INHIBITOR I
• CAS NO: 182912-74-9
• Molecular Formula: C₃₃H₄₃N₅O₈
• Molecular Weight: 637.72
• Product Categories: Alzheimers and Neurodegenerative Disease Research;Amyloid beta Protein Fragments;Amyloid β Protein FragmentsNeuropeptides;Neurodegenerative Disease Peptides;β Amyloid Peptides;peptide
• Mol File: 182912-74-9.mol

Chemical Properties

• Boiling Point: 980.0±65.0 °C(Predicted)
• Appearance: /solid
• Density: 1.291±0.06 g/cm3(Predicted)
• Storage Temp.: −20°C
• Solubility: ≥63.7 mg/mL in DMSO; ≥16.33 mg/mL in EtOH; ≥6.9 mg/mL in H2O with ultrasonic
• PKA: 2.88±0.10(Predicted)
• CAS DataBase Reference: (PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21)(CAS DataBase Reference)
• NIST Chemistry Reference: (PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21)(182912-74-9)
• EPA Substance Registry System: (PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21)(182912-74-9)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 182912-74-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21) is used as a target for the development of drugs and therapies aimed at treating Alzheimer's disease. Its role in the aggregation of amyloid beta-protein and the formation of amyloid plaques makes it a key factor in understanding the disease's progression and identifying potential intervention points.
Used in Diagnostics:
(PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21) can be used as a biomarker for Alzheimer's disease, helping in the early detection and diagnosis of the condition. The presence and levels of this peptide fragment in biological samples can provide valuable information on the disease's presence and progression.
Used in Neurodegenerative Disease Research:
(PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21) is used in research to understand the mechanisms behind neurodegenerative diseases, particularly Alzheimer's. Studying this peptide fragment can provide insights into the molecular and cellular processes that lead to neuronal damage and cognitive decline, potentially leading to the discovery of new therapeutic targets and strategies.
Used in Drug Screening:
(PRO18,ASP21)-AMYLOID BETA-PROTEIN (17-21) can be utilized in high-throughput screening assays to identify compounds that can inhibit the aggregation of amyloid beta-protein or disrupt the formation of amyloid plaques. This can accelerate the discovery of new drugs and therapeutic agents for the treatment of Alzheimer's disease and related neurodegenerative conditions.

Upstream product

• 35661-60-0 Fmoc-Leu-OH 
• 71989-31-6 Fmoc-Pro-OH 
• 35661-40-6 N-Fmoc L-Phe 

Relevant articles and documents

Acid-Triggered Colorimetric Hydrophobic Benzyl Alcohols for Soluble Tag-Assisted Liquid-Phase Synthesis

Simple screening of acid-triggered reactions of methoxybenzyl alcohols led to the development of a novel colorimetric hydrophobic benzyl alcohol (HBA) tag. HBA tag-3 (14) retained high solubility in less polar solvents and excellent precipitation properti

Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease

Alzheimer's disease (AD) is a devastating degenerative disorder of the brain for which there is no cure or effective treatment. There is much evidence to suggest that β-amyloid protein (Aβ) aggregation in the brain leading to deposits is an important step in the development of AD. Recently, two peptides, RGKLVFFGR (OR1) and RGKLVFFGR-NH2 (OR2) containing the sequence KLVFF, which is the central region (residues 16-20) of Aβ, have been found to be potent inhibitors of Aβ aggregate formation. Here we report that retro-inversion of these sequences increases efficacy of the peptides in the inhibition of aggregation and toxicity of β-amyloid. We describe the synthesis and inhibitory properties of these retro-inverso peptides.